Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials

about

Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials

Item

http://www.wikidata.org/entity/Q37221125

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Concordance of HIV-1 RNA Value ...... Suppression in Clinical Trials

@en

Concordance of HIV-1 RNA Value ...... uppression in Clinical Trials.

@nl

type

Item

label

Concordance of HIV-1 RNA Value ...... Suppression in Clinical Trials

@en

Concordance of HIV-1 RNA Value ...... uppression in Clinical Trials.

@nl

prefLabel

Concordance of HIV-1 RNA Value ...... Suppression in Clinical Trials

@en

Concordance of HIV-1 RNA Value ...... uppression in Clinical Trials.

@nl

P1476

Concordance of HIV-1 RNA Value ...... Suppression in Clinical Trials

@en

P2093

Javier Szwarcberg

http://www.w3.org/2001/XMLSchema#string

Kirsten White

http://www.w3.org/2001/XMLSchema#string

Lijie Zhong

http://www.w3.org/2001/XMLSchema#string

Mike Wulfsohn

http://www.w3.org/2001/XMLSchema#string

Scott McCallister

http://www.w3.org/2001/XMLSchema#string

Will Garner

http://www.w3.org/2001/XMLSchema#string

P2860

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.

Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.

Predictors of residual viraemia in patients on long-term suppressive antiretroviral therapy.

Comparative performances of HIV-1 RNA load assays at low viral load levels: results of an international collaboration.

Evolution in the sensitivity of quantitative HIV-1 viral load tests.

Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.

Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche AMPLICOR Version 1.5 conventional PCR assay.

Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res

Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults.

P304

929-934

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV1034

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26689956

http://www.w3.org/2001/XMLSchema#string

P932

5006441

http://www.w3.org/2001/XMLSchema#string